The Form 3 filing is a prerequisite step for a pre-IPO insider holding 10%+ — it does not itself move the stock. However, it confirms that OrbiMed, a top healthcare venture firm, holds significant convertible preferred stock, indicating strong institutional backer alignment. Traders should watch for the S-1 registration statement (IPO filing) expected soon, as the conversion of these preferred shares upon IPO will determine the public float and insider lock-up expiration dynamics. No immediate trade set-up from this filing alone.
Price Chart
Executive Summary
OrbiMed Advisors partner Carl L. Gordon filed an initial Statement of Beneficial Ownership (Form 3) with the SEC for BlossomHill Therapeutics (BLSM), a pre-IPO clinical-stage biopharmaceutical company. The filing discloses Gordon's indirect beneficial ownership via OrbiMed Private Investments VIII, LP of 1,039,996 shares of Series A Preferred Stock (convertible into common stock at IPO) and 1,049,283 shares of Series B Preferred Stock (also convertible 1:1 into common at IPO). This is a routine filing required upon a 10%+ ownership threshold event — likely ahead of BlossomHill's anticipated IPO.
Key Facts
- Carl L. Gordon filed Form 3 as a reporting owner for BlossomHill Therapeutics (BLSM) on August 6, 2026.
- Gordon holds 1,039,996 shares of Series A Preferred Stock indirectly through OrbiMed Private Investments VIII, LP.
- Gordon holds 1,049,283 shares of Series B Preferred Stock indirectly through OrbiMed Private Investments VIII, LP.
- Each share of Series A and Series B Preferred Stock is convertible into 1 share of Common Stock upon the closing of the issuer's initial public offering without further consideration.
- The Preferred Stock has no expiration date.
- OrbiMed Advisors LLC may be deemed to have voting/investment power over these securities via its management committee (Gordon, W. Carter Neild, Geoffrey Hsu).
Financial Impact
No financial impact from this filing alone. It signals pre-IPO insider ownership structure with ~2.09 million shares convertible to common upon IPO.
Risk Factors
- The expected IPO may be delayed or priced below expectations, diluting the implied conversion value of the preferred stock.
- OrbiMed's large pre-IPO stake could create selling pressure after lock-up expiration (typically 180 days post-IPO).
- BlossomHill is a clinical-stage biopharma (SIC 2834) with no approved products — pipeline risk is high.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (BLSM) — Batch item 1 | 0001282930-26-000007 |
| Document: 0001282930-26-000007-index-headers.html | 0001282930-26-000007 |
| Document: 0001282930-26-000007-index.html | 0001282930-26-000007 |
| Document: 0001282930-26-000007.txt | 0001282930-26-000007 |
| 3 Filing (BLSM) — Batch item 5 | 0001282930-26-000007 |
| Document: 0001282930-26-000007-index-headers.html | 0001282930-26-000007 |
| Document: 0001282930-26-000007-index.html | 0001282930-26-000007 |
| Document: 0001282930-26-000007.txt | 0001282930-26-000007 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | Press Release | $21.34 $16.39 | ▲ +23.20% | ▲ +23.16% | $15.76 (+26.15%) |
Sep 18, 2026 5w ago | 8-K | $25.74 $13.94 | ▲ +45.84% | ▲ +46.05% | $15.76 (+38.77%) |
Sep 18, 2026 5w ago | Press Release | $25.74 $13.94 | ▼ −45.84% | ▼ −46.05% | $15.76 (−38.77%) |
Sep 15, 2026 6w ago | 8-K | $22.17 $15.48 | ▼ −30.18% | ▼ −33.15% | $15.76 (−28.91%) |
Aug 12, 2026 10w ago | Insider Cluster | $16.35 $20.86 | ▲ +27.58% | ▲ +29.33% | $15.76 (−3.61%) |
Aug 10, 2026 11w ago | Insider Cluster | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $15.76 (−4.60%) |
Aug 10, 2026 11w ago | 8-K | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $15.76 (−4.60%) |
Aug 7, 2026 11w ago | 424B4 | $15.99 $22.93 | ▲ +43.40% | ▲ +44.32% | $15.76 (−1.44%) |
Aug 7, 2026 11w ago | EFFECT | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $15.76 (−1.50%) |
Aug 6, 2026 11w ago | 3 | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $15.76 (−1.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers